Procalcitonin is a marker of significant interest in the medical field, particularly when it comes to diagnosing and managing infections. Produced in response to a bacterial infection, procalcitonin levels in the blood can help doctors determine the severity of an infection or sepsis, a life-threatening response to infection. Unlike other markers that may rise in various conditions, procalcitonin is relatively specific to bacterial infections, making it a valuable tool for clinicians. When a patient presents symptoms of an infection, measuring procalcitonin levels can aid in deciding whether antibiotics are needed, as elevated levels are often indicative of a bacterial cause. On the other hand, low levels of procalcitonin might suggest a viral infection or another non-bacterial cause, potentially guiding a clinician away from unnecessary antibiotic use. This distinction is crucial in the fight against antibiotic resistance, a growing concern in healthcare. Labs, like Labcorp, offer procalcitonin testing, providing clinicians with a quantitative measure of procalcitonin in the blood. This information, in conjunction with other clinical findings, helps healthcare providers make more informed decisions about diagnosis, the necessity of antibiotics, and, if used, monitoring the effectiveness of treatment. The use of procalcitonin as a biomarker is a testament to how advanced laboratory testing contributes to personalized and precise patient care.
This marker is useful:
→ to aid in the risk assessment of critically ill patients on their first day of ICU admission for progression to severe sepsis and septic shock;
→ to determine the change in PCT level over time as an aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission;
→ to aid in decision making on antibiotic therapy, for inpatients or patients in the emergency department with suspected or confirmed lower respiratory tract infections (LRTI) — defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD);
→ to aid in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.